RxDoctor Payments Data

Anthony Smeglin

Interventional Cardiology · Cherry Hill, NJNPI 1992739668

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,854 of the $8,613 with a category attached, or 68.0%. 29 manufacturers reported payments, led by Cagent Vascular Inc at 27.9% of the total. 2025 is the largest year on record at $3,894, 4.9 times the $801 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in NJ, where the typical reported total is $8,550.

$8,613in general payments, 2019–2025

Across 172 payments — averaging $50.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cagent Vascular Inc$2K
  • Shockwave Medical, Inc$2K
  • Boston Scientific$669
  • Penumbra, Inc.$638
  • Siemens Medical Solutions USA, Inc.$459
  • Avinger Inc.$457
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$2,40028%
  • Travel & lodging$3604%
  • Food & beverage$5,85468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,613 in reported general payments places this provider in the 50th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$211,328
Medicare patients
384
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl23$12,698
ClopidogrelClopidogrel Bisulfate75$845
Atorvastatin Calcium22$188
Gabapentin15$116
Furosemide19$50

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Cherry Hill

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →